PPAR-γ Regulates Carnitine Homeostasis and Mitochondrial Function in a Lamb Model of Increased Pulmonary Blood Flow

Shruti Sharma1,*, Xutong Sun1,*, Ruslan Rafikov1, Sanjiv Kumar1, Yali Hou1, Peter E. Oishi2, Sanjeev A. Datar2, Gary Raff4, Jeffrey R. Fineman2,3, Stephen M. Black1*

1 Vascular Biology Center, Georgia Health Sciences University, Augusta, Georgia, United States of America, 2 Department of Pediatrics, University of California San Francisco, San Francisco, California, United States of America, 3 Cardiovascular Research Institute, University of California San Francisco, San Francisco, California, United States of America, 4 Department of Surgery, University of California Davis, Davis, California, United States of America

Abstract

Objective: Carnitine homeostasis is disrupted in lambs with endothelial dysfunction secondary to increased pulmonary blood flow (Shunt). Our recent studies have also indicated that the disruption in carnitine homeostasis correlates with a decrease in PPAR-γ expression in Shunt lambs. Thus, this study was carried out to determine if there is a causal link between loss of PPAR-γ signaling and carnitine dysfunction, and whether the PPAR-γ agonist, rosiglitazone preserves carnitine homeostasis in Shunt lambs.

Methods and Results: siRNA-mediated PPAR-γ knockdown significantly reduced carnitine palmitoyltransferases 1 and 2 (CPT1 and 2) and carnitine acetyltransferase (CrAT) protein levels. This decrease in carnitine regulatory proteins resulted in a disruption in carnitine homeostasis and induced mitochondrial dysfunction, as determined by a reduction in cellular ATP levels. In turn, the decrease in cellular ATP attenuated NO signaling through a reduction in eNOS/Hsp90 interactions and enhanced eNOS uncoupling. In vivo, rosiglitazone treatment preserved carnitine homeostasis and attenuated the development of mitochondrial dysfunction in Shunt lambs maintaining ATP levels. This in turn preserved eNOS/Hsp90 interactions and NO signaling.

Conclusion: Our study indicates that PPAR-γ signaling plays an important role in maintaining mitochondrial function through the regulation of carnitine homeostasis both in vitro and in vivo. Further, it identifies a new mechanism by which PPAR-γ regulates NO signaling through Hsp90. Thus, PPAR-γ agonists may have therapeutic potential in preventing the endothelial dysfunction in children with increased pulmonary blood flow.

Introduction

Carnitine is present in the form of either free carnitine (non-esterified molecule; FC), or acyl carnitines (esterified form; AC). A low AC/FC ratio is indicative of healthy mitochondria whereas a high AC/FC ratio suggests a decreased mitochondrial capacity for energy production. Carnitine and its derivatives are involved in the mitochondrial transport of fatty acids and are critical for the cell to maintain normal mitochondrial function. It is well established that the disruption of carnitine metabolism leads to mitochondrial dysfunction in cells. However, the mechanisms regulating carnitine metabolism are still unresolved. Our previous studies have identified a progressive endothelial dysfunction in a lamb model (Shunt) that mimics congenital heart disease with increased pulmonary blood flow [1]. This correlated with decreased expression and activity of mitochondrial enzymes involved in carnitine metabolism, disrupted carnitine homeostasis, and mitochondrial dysfunction [2].

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that belong to the nuclear hormone receptor family. Recent evidence has established a role for altered PPAR signaling in the development of both systemic and pulmonary vascular disease [3]. PPAR-γ in particular has been shown to play an important role in a number of pathological conditions including diabetes, inflammation, cancer, and atherosclerosis [4,5]. Recent experimental studies also suggest that loss of PPAR-γ signaling may be involved in the progression of pulmonary hypertension in models of adult [6,7] and childhood [8] disease. PPAR-γ signaling has been shown to be involved in...
regulating NO bioavailability [9,10,11] although the mechanisms have not been fully elucidated. Prior studies have also indicated a role for PPAR-γ signaling in the regulation of fatty acid metabolism through its ability to modulate the expression of genes involved in the carnitine pathway [12,13,14,15]. As our recent studies have shown that disruptions in carnitine homeostasis [2] correlate with a decrease in PPAR-γ expression [8] and increased NOS-uncoupling [2], this study was designed to determine if the attenuated PPAR-γ signaling in Shunt lambs is directly linked to the disruption of carnitine homeostasis, mitochondrial dysfunction and reduced NO signaling and to determine if PPAR-γ stimulation can preserve endothelial function in Shunt lambs.

**Methods**

**Pulmonary arterial endothelial cell (PAEC) culture**

Primary cultures of ovine fetal pulmonary arterial endothelial cells (PAEC) were isolated as described previously [16]. All cultures were maintained in Dulbecco’s modified eagle medium (DMEM) supplemented with 10% fetal calf serum (Hyclone, Logan, UT), antibiotics/antimycotic (500 IU Penicillin, 500 μg/ml Streptomycin, 1.25 μg/ml Amphotericin B; MediaTech, Herndon, VA) at 37°C in a humidified atmosphere with 5% CO2 and 95% air. Cells were used for experiments between passages 3 and 10, seeded at 0.1 ml Streptomycin, 1.25 μg/ml. Transfections were performed using the HiPerfect transfection reagent (Santa Cruz Biotechnology, sc-156097) or as a control, a lipophilic cation 10 μM Mitotracker green (Molecular Probes, Eugene, OR) was used according to the manufacturer’s protocol.

**Targeting silencing of PPAR-γ by small-interfering RNA**

To silence PPAR-γ gene expression, PAEC were grown in 6-well plates to ~60% confluence and transfected with optimized concentrations of sheep PPAR-γ small interfering RNA (siRNA) (Santa Cruz Biotechnology, sc-156097) or as a control, a scrambled siRNA (Santa Cruz Biotechnology, sc-37007) with no known homology to any sequences from mouse, rat, or human RNA. Transfections were performed using the HiPerfect transfection reagent (Qiagen, cat # 301705) and 25 nM of the appropriate siRNA. After 48 h, whole cell lysates were prepared and the level of PPAR-γ knockdown confirmed using Western blot analysis. PPAR-γ transfected cells were also treated with Rosiglitazone (10 μM) for 24 h and PPAR-γ binding activity, MitoSOX and mitochondrial membrane potential (MMP) studies were conducted as described below.

**PPAR-γ transcriotional activity assay**

The PPAR-γ Transcription Factor Assay kit (Cayman Chemical Company, Ann Arbor, MI) was used according to the manufacturer’s protocol.

**Determination of mitochondrial ROS levels**

MitoSOX® Red mitochondrial superoxide indicator (Molecular Probes), a fluorogenic dye for selective detection of superoxide in the mitochondria of live cells was used. The MitoSOX Red reagent is live-cell permeant and is rapidly and selectively targeted to the mitochondria. Once in the mitochondria, MitoSOX Red reagent is oxidized by superoxide and exhibits bright red fluorescence upon binding to nucleic acids. After siRNA mediated PPAR-γ silencing, cells were washed with fresh media, and then incubated in media containing MitoSOX Red (2 μM), for ~30 min at 37°C in dark conditions. Cells were washed with fresh serum-free media and imaged using fluorescence microscopy at an excitation of 510 nm and an emission at 580 nm. A PC-based imaging system consisting of the following components was used for the fluorescent analyses: an Olympus IX71 microscope equipped with a CCD camera (Hamamatsu Photonics) was used for acquisition of fluorescent images. The average fluorescent intensities (correct for differences in cell number) were quantified using ImagePro Plus version 5.0 imaging software (Media Cybernetics) as previously published [20].

**Analysis of mitochondrial membrane potential**

Mitochondrial membrane potential was analyzed using the DePsipher mitochondrial potential assay kit (Trevena, Gaithersburg, MD) as previously described [21,22]. Briefly, cells were washed with fresh media, and then the lipophilic cation 5,5'-tetrachloro-1,1'-3,3'-tetraethyl benzimidazolyl carboxyamine iodide (10 μg/ml) was added. The samples were then incubated for a further 20 min. After an additional wash with Dulbecco’s PBS, the red multimeric form within healthy mitochondria was quantified by fluorescence microscopy at 530 nm emission.

**Determination of mitochondrial numbers using Mitotracker green**

The total mitochondrial numbers in scrambled and PPAR-γ siRNA transfected ovine PAEC were evaluated by fluorescent microscopy and Fluorescence-Activated Cell Sorting (FACS) using Mitotracker green (Invitrogen, cat # M7514). Cells were stained with Mitotracker dye (100 nM) for 30 min at 37°C. Immunofluorescent images were acquired on an Applied Precision, Delta Vision microscope and the data presented as mean fluorescent intensity. For FACS analysis, after Mitotracker dye exposure, the cells were collected by trypsinization, washed twice with cold PBS, and analyzed by flow cytometry. Fluorescence was quantified using a FACS Calibur Flow Cytometer (BD Biosciences). The data was analyzed using the Cell Quest software and presented as total fluorescent intensity (mean fluorescent intensity x total number of cells).

**Determination of cellular ATP levels**

ATP levels were estimated using the firefly luciferin-luciferase method (Invitrogen) as previously published [2].

**Real time quantitative (q) RT-PCR**

Quantitative RT-PCR using SYBR green I dye for specific detection of double-stranded DNA was employed to determine CPT1, CPT2 and CrAT mRNA levels in scrambled siRNA and PPAR γ siRNA transfected (48 h) PAEC. Total RNA was extracted using the RNeasy kit (Qiagen), and 1 μg total RNA was reverse-transcribed using QuantiTect Reverse Transcription Kit (Qiagen) in a total volume of 20 μl. Primers for CPT1, CPT2, CrAT and β-actin were designed by Primer 3. The sequences were CPT1 Forward, 5'- CGA CGT GTG GGA GGA ATA CA -3', Reverse, 5'-TGC GTC TGT AAA GCA GGA TG -3'; CPT2 Forward, 5'-TTG TGC CTT CCT TCG TGT CT -3', Reverse, 5'-GAG GTG TCT GGC CTT GTC AT -3'; CrAT Forward, 5'- GTT CAG CAG CAG CAA GAA GC -3', Reverse, 5'-TGC AGT GAC GAG TCC CAG AC -3'; β-actin Forward, 5'-GGG AAA TCG TGC GTG ACA TTA AG -3', Reverse, 5'-TGT GTC TGC GTA AGG TCT TT -3'. Real-time Quantitative PCR was conducted using a Mx4000 Multiplex Quantitative PCR System (Stratagene), using 2 μl of RT product, 12.5 μl of
QuantiTect SYBR Green PCR Master Mix (Qiagen) and primers (400 nM) in a total volume of 25 µl. The following thermocycling conditions were employed: 95°C for 10 min, followed by 95°C for 30 s, 55°C for 60 s and 72°C for 30 s for 40 cycles. 2^{△△Ct} values were chosen to reflect the number of mRNA molecules using β-actin (housekeeping gene) as an internal control.

**Surgical Preparation**

Ten mixed-breed Western pregnant ewes (137–141 days gestation, term = 145 days) were anesthetized with the use of local anesthesia (2% lidocaine hydrochloride), and induced anesthesia (1–3% isoflurane). The pregnant horn of the uterus was exposed, followed by the left fetal chest. With the use of side biting vascular clamps, an 8.0 mm Gore-tex® vascular graft (~2 mm length) (W.L. Gore and Assos., Milpitas, CA) was anastomosed between the ascending aorta and main pulmonary artery with 7.0 proline (Ethicon Inc., Somerville, NJ), using a continuous suture technique. This procedure was previously described in detail [23]. Beginning immediately after birth, lambs were treated with either Rosiglitazone (n = 5, 3 mg/kg/day) or empty gelatin capsules (n = 5, vehicle control). The drug or vehicle capsules were administered once daily for a 4-week period. The number of vehicle capsules administered was increased to match the upwardly adjusted weight-based dosing of Rosiglitazone. Control groups were left untreated. All protocols and procedures were approved by the Committee on Animal Research of the University of California, San Francisco and the Georgia Health Sciences University.

**Western blot analysis**

Protein extracts from peripheral lung tissue or PPAR-γ transfected cells were prepared using lysis buffer (50 mM Tris-HCl, pH 7.6, 0.5%Triton X-100, 20% glycerol) containing Halt™ protease inhibitor cocktail (Pierce Laboratories, Rockford, IL). The extracts were then subjected to centrifugation (15,000 g×15 min at 4°C). Supernatant fractions were assayed for protein concentration using the Bradford reagent (Bio-Rad, Richmond, CA) and used for Western blot analyses. Protein extracts (25–50 µg) were separated on Long-Life 4–20% Tris-SDS-Hepes gels (Frenchs Forest, Australia) and electrophoretically transferred to Immuno-Blot™ PVDF membrane (Bio-Rad Laboratories, Hercules, CA). The membranes were blocked with 5% nonfat dry milk in Tris-buffered saline containing 0.1% Tween 20 (TBST). After blocking, the membranes were probed with antibodies to CPT1 (Affinity Bioreagents), CPT2 (Affinity Bioreagents), CrAT (Santa Cruz Biotechnology, Inc.), eNOS (BD Transduction Laboratories), Hsp90 (Santa Cruz Biotechnology, Inc.), and PPAR-γ (Santa Cruz Biotechnology, Inc.). Reactive bands were visualized using chemiluminescence (SuperSignal® West Femto Substrate Kit, Pierce Laboratories, Rockford, IL) on a Kodak 440CF image station (Kodak, Rochester, NY). Band intensity was quantified using Kodak 1D image processing software. Expression of each protein was normalized by reprobing with β-actin used as an equal loading control (Sigma, St.Louis, MO).

**Measurement of CrAT activity**

Peripheral lung tissue or PPAR-γ transfected cells were lysed in 50 mM Tris-HCl (pH 7.5), 2 mM EDTA, 5 mM MgCl2, 0.8 mM DTT, and 0.25 mM PMSF with protease inhibitor cocktail. Samples were briefly sonicated and centrifuged at 3000×g for 5 min. CrAT activity was then determined using a modification of the method described by Liu et al [24]. The assay mixture consisted of 50 mM Tris-HCl (pH 7.5), 2 mM EDTA, 25 mM malate, 0.25 mM NAD, 12.5 µg/ml rotenone, 0.04% Triton X-100, 12.5 µg/ml malic dehydrogenase, 17.5 µg/ml citrate synthase, 400 µM CoA, and 2 mM ALCAR. Each sample with a protein concentration between 0.5 mg/ml and 1.0 mg/ml was added to the assay mixture and reactions were monitored at room temperature for 3 minutes at 340 nm absorbance using a Shimadzu Pharmaspec UV-1700 spectrophotometer. The nmoles of product formed was calculated using the extinction coefficient of NADH.

**Measurement of Carnitine homeostasis**

For free carnitine (L-carnitine and acetyl L-carnitine) determination, 100 µl homogenates, 300 µl water and 100 µl of internal
standard (Sigma ST1093) were mixed. For total carnitine determination 100 mL homogenates were hydrolyzed with 0.3 M KOH, heated at 45°C, pH neutralized using perchloric acid, the volume was made to 400 mL and 100 mL internal standard was added. All samples were purified using solid phase extraction columns, SAX 100 mg/ml (Varian, Harbor City, CA) and derivatized using aminoanthracene in presence of EDCI (catalyst) and kept at 30°C for 1 hour to complete reaction of carnitines. Separation was carried out with an isocratic elution in 0.1 M Tris-acetate buffer (pH 3.5): acetonitrile (68:32, v/v) at a flow rate of 0.9 mL/min. Detection of carnitines was performed using a Shimadzu UFLC system with a 5 μm Omnispher C18 column (250 x 4.6 mm OD) and equipped with an RF-10AXL fluorescence detector (Shimadzu USA Manufacturing Corporation).

Immunoprecipitation analyses
PAEC were lysed in ice cold lysis buffer containing 1% Triton X-100, 20 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1% sodium deoxycholate, 0.1% SDS supplemented with protease inhibitor cocktail (Pierce Laboratories, Rockford, IL). Insoluble proteins were removed by centrifugation at 14,000 rpm for 15 min at 4°C and supernatants were incubated with anti-eNOS antibody (BD Transduction Laboratories) overnight at 4°C and then with protein G plus/protein A agarose suspension (Calbio-
Figure 3. Decreased PPAR-γ signaling induces mitochondrial dysfunction in ovine pulmonary arterial endothelial cells. PAEC were transiently transfected with a PPAR-γ siRNA or a scrambled siRNA for 24 h then exposed or not to the PPAR-γ agonist, rosiglitazone (10 μM) for a further 24 h. The MitoSOX red mitochondrial ROS indicator was then added. Representative images after MitoSOX staining are shown (A, top). Images of 20 random fields were quantified to determine the mean fluorescence intensity of each sample. PPAR-γ inhibition significantly increased
mitochondrial ROS levels and this was reversed by rosiglitazone (A). Mitochondrial membrane potential (MMP) was also determined using the DePsipher mitochondrial potential assay kit. Representative images after DePsipher staining are shown (B, top). PPAR-γ inhibition significantly decreased mitochondrial membrane potential and this was reversed by rosiglitazone (B). Total mitochondrial number was evaluated by fluorescent microscopy (C) and flow cytometry (D) in scrambled and PPAR-γ siRNA transfected PAEC stained with Mitotracker green. PPAR-γ gene silencing had no significant affect on mitochondrial number as evaluated by either method. There was also a significant reduction in ATP levels after PPAR-γ siRNA transfection (E). Values are mean ± SE; n = 7–12. *P<0.05 vs scrambled siRNA.

doi:10.1371/journal.pone.0041555.g003

chym, La Jolla, CA) for 2 h at 4°C for eNOS/Hsp90 immuno-precipitation studies. The immune complexes were precipitated by centrifugation, washed three times with the lysis buffer and boiled in SDS sample buffer for 5 min. Agarose beads were pelleted by centrifugation, and protein supernatants were loaded and run on (4–20%) polyacrylamide gels followed by transfer of the proteins to nitrocellulose membranes. Membranes was blocked with 2% BSA in Tris-buffered saline containing 0.05% Tween 20 (TBST) for 2 h at room temperature, incubated with an anti-Hsp90 antibody (BD transduction Laboratories, Rockford, IL). The reactive bands were visualized with the SuperSignal West Femto Maximum Sensitivity Substrate Kit (Pierce Laboratories, Rockford, IL) and Kodak 440CF image station (Kodak, New Haven, CT). The same blot was re-probed with anti-eNOS antibody to normalize for the levels of immuno-precipitated-eNOS in each sample or re-probed with anti-Hsp90 to normalize for total Hsp90 levels.

Measurement of NOS-derived superoxide levels in PAEC and lung tissue

Superoxide levels in PPAR-γ siRNA transfected endothelial cells subjected to shear and lung tissues from control, shunt and rosiglitazone-treated shunt lambs, were estimated by electron paramagnetic resonance (EPR) assay using the spin-trap compound 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrroli-dine HCl (CMH, Axxora) as described previously [25,26]. Superoxide in PAEC was trapped by incubating PAEC with 20 μl of CMH stock solution (20 mg/ml) for 1 h, followed by trypsinization and centrifugation at 500 g. The cell pellet was suspended in 35 μl DPBS and loaded into a capillary tube which was then analyzed with a MiniScope MS200 EPR machine (Magnettech, Berlin, Germany). Freshly frozen lung tissues were pulverized (10–15 mg) and then, homogenized in 150 μl of EPR buffer for 30 s for measurement of superoxide. Sample volumes were then adjusted with 20 μg/ml CMH hydrochloride to achieve final CMH concentration of 10 μg/ml. 35 μl of supernatant was loaded onto a capillary tube and analyzed using the EPR machine. NOS-derived superoxide was measured by pre-incubating tissue lysate with 100 μM ethylisothiourea (ETU, Sigma-Aldrich) for 30 min followed by incubation with CMH. EPR spectra were analyzed using ANALYSIS v.2.02 software (Magnettech). Differences between levels of samples incubated in the presence and absence of ETU were used to determine NOS-dependent superoxide generation. eNOS-dependent superoxide levels were reported as nmols/min/mg protein.

Measurement of NOx levels in PAEC and lung tissue

To measure NOx level in tissue samples we utilized a chemiluminescence method. Samples were deproteinized by adding cold ethanol (1:4; v/v). 0.05 g of potassium iodide (KI) was dissolved in 7 ml of freshly prepared acetic acid (AA). The KI/AA reagent was added to a septum sealed purge vessel and bubbled with nitrogen gas. The gas stream was connected via a trap containing 1N NaOH to a Sievers 280 Nitric Oxide Analyzer (GE). Deproteinized samples were injected with a syringe through a silicone/Teflon septum. Results were analyzed by measuring the area under curve of the chemiluminescence signal using the Liquid software (GE).

**Determination of lactate and pyruvate levels**

Lung tissues were homogenized in ice-cold 0.5 M perchloric acid then centrifuged at 14,000 rpm for 20 min. The supernatants were then neutralized with 3 M KHCO3 and used for lactate and pyruvate assays. The relative changes in lactate levels were measured by using lactate assay kit (Biovision). Pyruvate levels were determined using the spectrophotometric enzymatic measurement assay at 340 nm. NADH was used as a cofactor and lactate dehydrogenase (LDH) as the co-enzyme. Experimental conditions were as previously published [27].

**Statistical analyses**

This was performed using GraphPad Prism version 4.01 for Windows (GraphPad Software, San Diego, CA). The mean ± SEM were calculated for all samples and significance was determined either by the unpaired t-test (for 2 groups) or by ANOVA (for ≥3 groups). When the data was non-normally distributed, non-parametric testing was used (Wilcoxon signed-rank for 2 groups, and the Kruskal-Wallis test for ≥3 groups). A value of p<0.05 was considered significant.

**Results**

PPAR-γ siRNA significantly decreases PPAR-γ expression and activity in pulmonary arterial endothelial cells

PAEC were transiently transfected with a PPAR-γ siRNA or a scrambled siRNA and the level of PPAR-γ knockdown was confirmed using Western blot analysis. There was a significant (>50%) reduction in PPAR-γ protein levels in PPAR-γ siRNA transfected cells (Figure 1 A). PPAR-γ binding activity was also significantly decreased in PPAR-γ siRNA transfected cells, and this was reversed after treatment with the PPAR-γ agonist, rosiglitazone (Figure 1 B).

Attenuating PPAR-γ signaling disrupts carnitine homeostasis in pulmonary arterial endothelial cells

The effect of reducing PPAR-γ signaling on cellular carnitine homeostasis was determined using HPLC analysis. PPAR-γ siRNA transfection led to a significant increase in acyl carnitine levels (Figure 2 A) and an increased AC/FC ratio (Figure 2 B). Further, the disruption in carnitine homeostasis correlated with a significant decrease in CPT1- (Figure 2 D), CPT2- (Figure 2 F), and CrAT (Figure 2 H)-protein levels as well as CrAT activity (Figure 2 I). Further, there was a significant decrease in CPT2 mRNA levels (Figure 2 E) but CPT1 and CrAT mRNA levels did not change (Figure 2 C & G).
Disruption of carnitine homeostasis disrupts mitochondrial function, decreases eNOS/Hsp90 interactions and causes eNOS uncoupling

As our data indicated that the percentage of carnitine present in its acylated form is increased when PPAR-γ signaling is attenuated, we next examined its effect on mitochondrial function. Suppressing PPAR-γ expression produced a significant increase in mitochondrial ROS levels (Figure 3 A) and mitochondrial membrane potential (Figure 3 B). Treatment with the PPAR-γ agonist, rosiglitazone was able to reverse these changes (Figure 3 A & B). There was no change in the total mitochondrial numbers in the scrambled and PPAR-γ siRNA as determined by Mitotracker staining (Figure 3 C) and FACS analysis (Figure 3 D). However, there was a reduction in cellular ATP levels (Figure 3 E), indicating that the loss of carnitine homeostasis induced by the attenuation of PPAR-γ signaling leads to mitochondrial dysfunction. Hsp90 is an ATP dependent chaperone and the interaction of Hsp90 with eNOS has been shown to increase eNOS coupling and NO production [25]. Thus, we next examined the effect of the decrease in cellular ATP levels on eNOS/Hsp90 interactions. We did not find any change in the eNOS and Hsp90 protein levels (Figure 4 A & B) after PPAR-γ gene silencing. However, utilizing immunoprecipitation analyses we found that decreasing PPAR-γ signaling significantly decreased the binding of Hsp90 to eNOS (Figure 4 C). In addition, we found that in response to acute shear stress, eNOS dependent superoxide generation was enhanced (Figure 4 D) while NO production was reduced (Figure 4 E) in PPAR-γ siRNA transfected cells. Basal superoxide production and NO generation were unaffected by PPAR-γ siRNA transfection. Together these data indicate that the impaired mitochondrial function induced by PPAR-γ inhibition leads to uncoupling of eNOS and reduced NO signaling.

The PPAR-γ agonist, rosiglitazone preserves carnitine homeostasis in lambs with increased pulmonary blood flow

We have previously shown that both PPAR-γ signaling [8] and carnitine homeostasis are disrupted in Shunt lambs. Thus, we next determined whether the PPAR-γ agonist, rosiglitazone could preserve carnitine homeostasis in these lambs. Compared to age-matched Control lambs, CPT1 (Figure 5 A) and CrAT (Figure 5 C) protein levels are reduced in vehicle-treated Shunt lambs, although CPT2 protein was unchanged (Figure 5 B). Rosiglitazone treatment preserved CPT1 (Figure 5 B) and CrAT protein levels (Figure 5 C) and prevented the decrease in CrAT activity in Shunt treatment preserved CPT1 (Figure 5 B) and CrAT protein levels (Figure 5 C) protein levels are reduced in vehicle-treated Shunt lambs, matched Control lambs, CPT1 (Figure 5 A) and CrAT (Figure 5 D). Carnitine homeostasis was also preserved (Figure 5 E & F).

Rosiglitazone preserves mitochondrial function in lambs with increased pulmonary blood flow

Shunt lambs have mitochondrial dysfunction, exhibiting significantly higher UCP-2 protein levels (Figure 6 A), a higher lactate/ pyruvate ratio (Figure 6 B), and reduced ATP levels (Figure 6 C) compared to age-matched controls. Rosiglitazone treatment prevented the increase in UCP-2 protein levels (Figure 6 A), the disruption of the lactate/pyruvate ratio (Figure 6 B), and the reduction in ATP levels (Figure 6 C) indicative of improved mitochondrial function.

Rosiglitazone restores eNOS/Hsp90 interactions and NO generation in lambs with increased pulmonary blood flow

Our data indicate that the decreased association of eNOS with Hsp90 in Shunt lambs correlating with reduced ATP levels is attenuated by rosiglitazone (Figure 7 A). Further, the increase in eNOS uncoupling (Figure 7 B) and reductions in NO generation (Figure 7 C) in Shunt lambs was prevented by rosiglitazone indicating that endothelial function is preserved.

Discussion

An expanding body of literature has established the importance of endothelial dysfunction in the pathogenesis of pulmonary vascular disease. However, a consensus on what defines endothelial dysfunction has not emerged. At present a number of factors are used to define this process, including alterations in structure, perturbations in the normal production and/or balance of endothelial-derived factors, and functional abnormalities, including increased constriction and/or impaired relaxation. It is clear that the mechanisms responsible for these signaling and structural changes are multi-factorial and this study provides insight into a novel mechanism by which the attenuation of PPAR-γ signaling reduces NO signaling in PAEC through mitochondrial dysfunction. The important findings of this study are: (i) PPAR-γ inhibition decreases the expression proteins involved in carnitine metabolism resulting in the disruption of carnitine homeostasis; (ii) The disruption in carnitine homeostasis leads to mitochondrial dysfunction and decreased cellular ATP generation; (iii) The decrease in cellular ATP levels disrupts the cNOS-Hsp90 interaction leading to cNOS uncoupling and decreased NO signaling; (iv) The PPAR-γ agonist, rosiglitazone preserves mitochondrial- and endothelial-function in lambs with increased pulmonary blood flow.

PPAR-γ signaling has a major impact on endothelial biology [3,28,29] and alterations in PPAR-γ function appear to play a role in the pathogenesis of pulmonary hypertension, diabetes, atherosclerosis, inflammation, and cancer [4,5,6]. Prior studies have identified interactions between PPAR-γ and factors believed to be important for the progression of pulmonary vascular disease including NO, endothelin-1, prostacyclin, asymmetric dimethylarginine, insulin, and the bone morphogenetic protein pathway [30,31,32,33,34,35,36,37]. Earlier studies have identified a decrease in PPAR-γ mRNA [38] and protein expression in lungs from patients with pulmonary hypertension [6] while rosiglitazone, a PPAR-γ agonist, has been shown to attenuate hypoxia-induced pulmonary hypertension, vascular remodeling, and reactive oxygen species generation in the mouse lung [39,40]. We also recently reported that PPAR-γ protein levels are significantly down-regulated in the lung of our lamb model of...
Figure 5. Rosiglitazone treatment preserves carnitine homeostasis in lambs with increased pulmonary blood flow. Protein extracts (50 μg) were prepared from peripheral lung tissues from vehicle- or rosiglitazone-treated Shunt lambs and age-matched controls. CPT1, CPT2 and CrAT protein levels were then determined by Western blot analyses. There was a significant decrease in CPT1 (A) and CrAT (C) protein levels in the vehicle-treated Shunt lambs. Rosiglitazone treatment prevented the decrease in the protein levels of CrAT enzyme (C). There was no significant change in the CPT2 protein levels (B) in any of the 3 groups. There was also a significant decrease in CrAT activity in vehicle-treated Shunt lambs, which was prevented by rosiglitazone (D). Acyl carnitines (E) and the AC:FC ratio (F) were found to be significantly higher in the vehicle-treated Shunt lambs, indicating disruption of carnitine homeostasis. However, carnitine homeostasis was preserved by rosiglitazone treatment (E & F). Values are mean ± SE; n = 4–6 for each group. *P < 0.05 vs control; †P < 0.05 vs shunt. doi:10.1371/journal.pone.0041555.g005
pulmonary hypertension secondary to increased pulmonary blood flow (Shunt) [8] and this correlated with the disruption of carnitine homeostasis [2]. As the mitochondrial membrane is impermeable to long-chain fatty acids, carnitine is required for the transportation of fatty acids into the mitochondria so they are available for β-oxidation. Carnitines are also involved in the removal of accumulated toxic fatty acyl-CoA metabolites, and help in buffering the balance between free and acyl-CoA. The carnitine transport system consists of carnitine palmitoyltransferase 1 (CPT1) localized on the outer mitochondrial membrane and carnitine palmitoyltransferase 2 (CPT2) localized on the inner mitochondrial membrane [41]. PPARs have been shown to regulate the entry of fatty acids into the mitochondria by increasing the expression of the CPT1 gene [14]. This study also identified a PPAR response element (PPRE) in the promoter region of the CPT1 gene [14]. Further, the combined activation of PPAR-γ and β-adrenergic receptors in humans results in a beneficial effect on lipid metabolism in subcutaneous fat by increasing the expression of genes required for fatty acid catabolism which include CPT1 [12]. Also a 3-fold increase in PPAR-γ expression in skeletal muscle has been shown to produce a 13-fold change in expression of CPT1 [13]. Organ specific changes in PPAR-γ signaling can also alter systemic carnitine homeostasis as demonstrated in a recent study where PPAR-γ was over-expressed in the colon [42]. Similarly, our results show that PPAR-γ activation via rosiglitazone, preserved free carnitine levels and prevented the increase in acylcarnitines, thus improving carnitine homeostasis.

Our data also suggest that the regulation of the carnitine homeostatic enzymes by PPAR-γ is complex. In vitro, PPAR-γ gene silencing reduced the levels of CPT1 and CPT2 protein. At the mRNA level only CPT2 was reduced despite a PPAR response element (PPRE) having been identified in the CPT1 gene [14]. However, PPAR’s do not always act independently due to their

---

**Figure 6. Rosiglitazone treatment preserves mitochondrial function in lambs with increased pulmonary blood flow.** Protein extracts (50 μg) were prepared from peripheral lung tissues from vehicle- or rosiglitazone-treated Shunt lambs and age-matched controls. UCP-2 protein levels were then determined using Western blot analysis. There was a significant increase in UCP-2 protein levels in the vehicle-treated Shunt lambs (A). The increase in UCP-2 was not observed in Shunt lambs treated with rosiglitazone (A). There was also a significant reduction in lactate:pyruvate ratio (B) and ATP levels (C) in vehicle-treated Shunt lambs. However, both the lactate:pyruvate ratio and ATP levels were preserved by rosiglitazone and were unchanged compared to age-matched control lambs (B & C). Values are mean ± SE; n = 5–7 for each group. *P<0.05 vs control; †P<0.05 vs shunt.

doi:10.1371/journal.pone.0041555.g006
intrinsic ability to form hetero-complexes with other transcription factors that can then modulate their ability to bind to regulatory cis-elements. Thus, it is possible that there is a compensatory upregulation of a co-activator, or alternatively, a downregulation of a transcriptional repressor, that preserves CPT1 mRNA levels. We also found that the levels of CrAT protein are decreased both in siRNA expressing PAEC and in Shunt lambs while CrAT levels were preserved by rosiglitazone in Shunt lambs. However, in ovine PAEC, PPAR-γ gene silencing did not reduce CrAT mRNA levels. The gene for CrAT does not appear to have a PPRE sequence [43]. Thus, the down-regulation of CrAT that we have observed in response to decreases in PPAR-γ signaling is likely indirect. Taken together, we speculate that the reduction in CPT1 and CrAT protein in ovine PAEC, despite no reduction in mRNA levels, may be explained by an increase in their degradation. Indeed, we have recently shown, in both ovine PAEC and Shunt lambs, that mitochondrial dysfunction leads to an increase in the proteasomal degradation of GTP cyclohydrolase I [44,45]. However, further studies will be required to test this possibility. Further complexity is shown by the fact that although CrAT activity was significantly less in the 4-week Shunt lambs utilized in this investigation, the reduction was only 2-fold compared to the 10-fold we observed at 2-weeks of age again suggesting that mechanisms other than PPAR-γ signaling may be involved in regulating CrAT expression and activity. Also, in Shunt lambs CPT1 but not CPT2 protein levels were decreased. Why CPT2 levels are not decreased in Shunt lambs at 4-weeks of age is unclear, as we have previously shown a significant decrease at 2-weeks of age [2]. However, it is possible that factors other than PPAR-γ are also involved in regulating CPT2 expression in the pulmonary vessel. For example there is data suggesting that increases in TGF-β1 are inversely correlated with CPT expression.

Figure 7. Rosiglitazone treatment preserves NO signaling in lambs with increased pulmonary blood flow. The interaction of eNOS with Hsp90 was determined by immunoprecipitation using specific antiserum raised against eNOS using peripheral lung extracts prepared from vehicle- or rosiglitazone-treated Shunt lambs and age-matched controls. Immunoprecipitated extracts were analyzed using antiserum against either eNOS or Hsp90. The levels of eNOS protein associated with Hsp90 relative to total eNOS protein were calculated. There is a significant decrease in the association of eNOS with Hsp90 in vehicle-treated Shunt lambs, which is prevented by rosiglitazone (A). Further, there is an increase in NOS-derived superoxide generation (B) and decreased NOx levels (C) in vehicle-treated Shunt lambs, indicating increased eNOS uncoupling. Rosiglitazone treatment preserved eNOS coupling and both NOS-derived superoxide (B) and NOx (C) were unchanged to observed in age-matched control lambs. Values are mean ± SE; n = 4–8 for each group. *P<0.05 vs control; †P<0.05 vs shunt.

doi:10.1371/journal.pone.0041555.g007
rosiglitazone decreased the oxidative stress associated with increased pulmonary blood flow, at least in part, by preserving mitochondrial function and eNOS coupling. However, it is worth noting that the lung contains multiple potential sources for superoxide in addition to the mitochondrial and eNOS. These include NADPH oxidase, lipoygenase, cyclooxygenase, and xanthine oxidase. In addition, superoxide levels relate not only to its generation, but also to its metabolism and studies indicate that PPAR-γ activation can increase superoxide dismutase and catalase expression and activity [57,58]. However, determining whether rosiglitazone alters the activity of other superoxide generating systems or antioxidant enzymes in the Shunt lambs will require further studies. It is also worth noting that although we used a validated chemiluminescence method of detecting NO, and its metabolic products nitrite and nitrate, which together are termed NOx [39,60], the in vivo measurement of NO is difficult, as NO has a short half-life and reacts rapidly with ROS, oxygen, metals, sulphhydrils, disulphides, and hemoglobin [61]. Thus, it is likely that we are underestimating NO generation in the lung.

In conclusion our findings suggest that PPAR-γ can regulate the balance between NO bioavailability and superoxide generation through mechanisms that involve mitochondrial pathways. Inhibition of PPAR-γ in PAEC leads to a disruption in carnitine homeostasis and subsequent mitochondrial dysfunction. This in turn leads to a reduction in eNOS-Hsp90 interactions (secondary to decreased ATP generation) and reduced NO signaling. Rosiglitazone supplementation preserves mitochondrial function, and prevents endothelial dysfunction in vivo. Thus, we speculate that stimulating PPAR-γ signaling or enhancing carnitine homeostasis may have therapeutic benefits in conditions of endothelial dysfunction such as pulmonary hypertension, diabetes, and atherosclerosis.

Acknowledgments
The authors wish to thank Imran Rehmani, Suphin Kallarackal, and Michael Johengen for excellent technical help.

Author Contributions
Conceived and designed the experiments: SS XS RR SK JRF SMB. Performed the experiments: SS XS RR SK YH PO SD JRF SMB. Analyzed the data: SS XS RR SK YH PO SD JRF SMB. Wrote the paper: SS XS RR SK PO SD JRF SMB.

References
1. Sharma S, Grobe AC, Wiseman DA, Kumar S, Enghlath M, et al. (2007) Lung antioxidant enzymes are regulated by development and increased pulmonary blood flow. Am J Physiol Lung Cell Mol Physiol 293: L960–971.
2. Sharma S, Sud N, Wiseman DA, Carter AL, Kumar S, et al. (2008) Altered carnitine homeostasis is associated with decreased mitochondrial function and altered nitric oxide signaling in lungs with pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 294: L46–56.
3. Nielsen RE, Sultiff RL, Hart CM (2007) The role of peroxisome proliferator-activated receptors in pulmonary vascular disease. PPAR Res 2007: 18797.
4. Kersten S, Desvergne B, Wahli W (2000) Roles of PPARs in health and disease. Nature 405: 421–424.
5. Vamecq J, Latruffe N (1999) Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production. Am J Physiol Heart Circ Physiol 297: H1647–1654.
6. Bozacka I, Gettys TW, de Jonge L, Nguyen T, Smith JM, et al. (2007) The effect of rosiglitazone on target genes related to lipid metabolism in human subcutaneous adipose tissue. Diabetes Care 30: 1179–1186.
7. Tsujioka H, Kuroi A, Kurosaki A, Kobayashi K, et al. (2008) Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol 25: 1810–1816.
8. Ikejima H, Inamishi T, Tsujioka H, Kurosaki A, Kobayashi K, et al. (2008) Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change. J Hyper tension 26: 964–972.
9. Kleinhenz JM, Kleinhenz DJ, You S, Ritzenthaler JD, Hansen JM, et al. (2009) Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production. Am J Physiol Heart Circ Physiol 297: H1647–1654.
10. Polikandristis JA, Mazzella LJ, Rupnow HL, Hart CM (2005) Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol 25: 1810–1816.
11. Boppe GA, Gettys TW, de Jonge L, Nguyen T, Smith JM, et al. (2007) The effect of beta-adrenergic and peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change. J Hyper tension 26: 964–972.
12. Bogucka I, Gettys TW, de Jonge L, Nguyen T, Smith JM, et al. (2007) The effect of beta-adrenergic and peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change. J Hyper tension 26: 964–972.
15. Kim S, Soini I, Lee YS, Lee YS (2005) Heparin gene expression profiles are altered by genistein supplementation in mice with diet-induced hyperlipidemia. J Nutr 135: 33–41.

16. Kelly LK, Wedgwood S, Steinhorn RH, Black SM (2004) Nitric oxide decreases endothelin-1 secretion through the activation of soluble guanylate cyclase. Am J Physiol Lung Cell Mol Physiol 286: L984–991.

17. Wedgwood S, Mitchell CJ, Finean JR, Black SM (2003) Developmental differences in the shear stress-induced expression of endothelial NO synthase: a dynamic role of AP-1. Am J Physiol Lung Cell Mol Physiol 284: L630–632.

18. Wedgwood S, Bekker JM, Black SM (2001) Shear stress regulation of endothelial NO in fetal pulmonary arterial endothelial cells involves PKC. Am J Physiol Lung Cell Mol Physiol 281: L690–98.

19. Dewey CF Jr, Bussolari SR, Gimbrone MA Jr, Davies PF (1981) The dynamic response of vascular endothelial cells to fluid shear stress. J Biomech Eng 103: 177–183.

20. Sud N, Wells SM, Hubbard M, Welker JE, Black SM (2007) Alterations in zinc homeostasis underlie endothelial cell death induced by oxidative stress from acute exposure to hydrogen peroxide. Am J Physiol Lung Cell Mol Physiol 292: L165–177.

21. Reddy VM, Meyrick B, Wong J, Khoor A, Liddicoat JR, et al. (1995) Antiproliferative BMP-2/PPARgamma/apoE axis in human and mouse skeletal progenitor cells. J Endocrinol Invest 33: 9–12.

22. Hart CM, Roman J, Reddy R, Sime PJ (2008) PPARgamma: a novel molecular target in lung disease. J Investig Med 56: 515–517.

23. Liao J, Källå-KAW, Ames BN (2002) Age-associated mitochondrial oxidative decay: improvement of cardiac acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L-carnitine and/or R-alpha-lipoic acid. Proc Natl Acad Sci U S A 99: 1067–1071.

24. Marbach EP, Weil MH (1967) Rapid enzymatic measurement of blood lactate and pyruvate. Use and significance of metaphosphoric acid as a common precipitant. Clin Chem 13: 314–325.

25. Hart CM (2008) The Role of PPARgamma in pulmonary vascular disease. J Investig Med 56: 518–521.

26. Kerner J, Hoppel C (2000) Fatty acid import into mitochondria. Biochim Biophys Acta 1486: 1–17.

27. sud N, Sharma D, Wiseman DA, Harmon C, Kumar S, et al. (2007) Nitric oxide and superoxide generation from endothelial NO: modulation by HS90. Am J Physiol Lung Cell Mol Physiol 293: L1444–1453.

28. Lakshmimurthi N, Wiseman D, Black SM, Russell JA, Giugno SF, et al. (2007) The role of nitric oxide synthase-repressed reactive oxygen species in the altered relaxation of pulmonary arteries from lungs with increased pulmonary blood flow. Am J Physiol Heart Circ Physiol 293: H1491–1497.

29. Marbach EP, Weil MH (1967) Rapid enzymatic measurement of blood lactate and pyruvate. Use and significance of metaphosphoric acid as a common precipitant. Clin Chem 13: 314–325.

30. Nemenoff R, Meyer AM, Hudish TM, Mozer AB, Snee A, et al. (2008) Antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 118: 1646–1657.

31. Gupta D, Kono T, Evans-Molina C (2010) The role of peroxisome proliferator-activated receptors (PPAR) alpha, beta/delta or gamma in the development of thoracic aortic aneurysm. J Investig Med 58: 599–606.

32. Kim EK, Lee JH, Oh YM, Lee YS, Lee SD (2010) Rosiglitazone attenuates endothelial mitochondrial membrane potential using the J-aggregate forming lipophilic cation, 5,5′,6,6′-tetraethylrhodamine-1,3,3′,3′-tetrahydrobenzimidazolocarbocyanine iodide (JC-1). Biochem Biophys Res Commun 197: 40–45.

33. Nemenoff R, Meyer AM, Hudish TM, Mozer AB, Snee A, et al. (2008) Antiproliferative BMP-2/PPARgamma/apoE axis in human and mouse skeletal progenitor cells. J Endocrinol Invest 33: 9–12.

34. Liu Y, Zhu Y, Rannou F, Lee TS, Formentin K, et al. (2004) Laminar flow activates peroxisome proliferator-activated receptor-gamma in vascular endothelial cells. Circulation 110: 1129–1133.

35. Liu Y, Zhang Y, Schneller K, Lee TS, Fang X, et al. (2005) The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A 102: 16747–16752.

36. Konduri GG, Materi J (2002) Role of oxidative phosphorylation and ATP release in mediating birth-related pulmonary vasodilation in fetal lambs. Am J Physiol Heart Circ Physiol 283: H1600–1608.

37. Konduri GG, Mital S (2000) Adenosine and ATP cause nitric oxide-dependent pulmonary vasodilation in fetal lambs. Am J Physiol Lung Cell Mol Physiol 284: L299–305.

38. Brouet A, Sonceaux P, Desy C, Ballagand JL, Feron O (2001) Hsp90 enhances the transition from the early Ca2+-dependent to the late phosphorylation-dependent activation of the endothelial nitric-oxide synthase in vascular endothelial growth factor-exposed endothelial cells. J Biol Chem 276: 32663–32669.

39. Fontana J, Fulton D, Chen Y, Fairchild TA, McCabe TJ, et al. (2002) Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ Res 90: 866–873.

40. Garcia-Cardenas G, Fan R, Shah V, Sorrentino R, Cárino G, et al. (1998) Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 392: 599–603.

41. Mata-Greenwood E, Meyrick B, Steinhorn RH, Fineman JR, Black SM (2003) Alterations in TGF-beta1 expression in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 285: L209–221.

42. D'Argenio G, Petillo O, Margarucci S, Torpedine A, Calarco A, et al. (2010) Agonists of peroxisome proliferator-activated receptors (PPAR) alpha, beta/delta or gamma reduce transforming growth factor (TGF)-beta-induced protoglycan production in chondrocytes. Osteoarthritis Cartilage 15: 493–505.

43. van der Leij FR, Huijkman NC, Boomsma C, Kuipers JR, Bartelds B (2000) Genomics of the human carnitine acyltransferase genes. Mol Genet Metab 71: 139–153.

44. Sharma S, Sun X, Kumar S, Rafikov R, Aranburu A, et al. (2012) Preserving mitochondrial function preserves the proinflammatory degradation of GTP cyclohydrolase I. Free Radical Biology and Medicine 53: 216–229.

45. Sun X, Fratz S, Sharma S, Hou Y, Rafikov R, et al. (2011) C-terminal of heat shock protein 70-interacting protein-dependent GTP cyclohydrolase I degradation in lambs with increased pulmonary blood flow. American Journal of Respiratory and Cellular Medicine 185: 163–171.

46. Poleni PE, Bianchi A, Erienne S, Koufany M, Sebillaud S, et al. (2007) Agents of peroxisome proliferator-activated receptors (PPAR) alpha, beta/delta or gamma reduce transforming growth factor (TGF)-beta-induced protoglycan production in chondrocytes. Osteoarthritis Cartilage 15: 493–505.

47. Mata-Greenwood E, Meyrick B, Steinhorn RH, Fineman JR, Black SM (2003) Alterations in TGF-beta1 expression in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 285: L209–221.

48. Liu Y, Zhu Y, Rannou F, Lee TS, Formentin K, et al. (2004) Laminar flow activates peroxisome proliferator-activated receptor-gamma in vascular endothelial cells. Circulation 110: 1129–1133.

49. Liu Y, Zhang Y, Schneller K, Lee TS, Fang X, et al. (2005) The anti-inflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A 102: 16747–16752.

50. Fontana J, Fulton D, Chen Y, Fairchild TA, McCabe TJ, et al. (2002) Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ Res 90: 866–873.

51. Garcia-Cardenas G, Fan R, Shah V, Sorrentino R, Cárino G, et al. (1998) Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 392: 599–603.